Literature DB >> 30879200

Understanding CGRP and Cardiovascular Risk.

Eloísa Rubio-Beltrán1, Antoinette Maassen van den Brink2.   

Abstract

Increasing knowledge about the role of calcitonin gene-related peptide (CGRP) in migraine pathophysiology has led to the development of antibodies against this peptide or its receptor. However, CGRP is widely expressed throughout the body, participating not only in pathophysiological conditions but also in several physiological processes and homeostatic responses during pathophysiological events. Therefore, in this chapter, the risks of long-term blockade of the CGRP pathway will be discussed, with focus on the cardiovascular system, as this peptide has been described to have a protective role during ischemic events, and migraine patients present a higher risk of stroke and myocardial infarction.

Entities:  

Keywords:  CGRP; CGRP (receptor) antibodies; Cardiovascular safety; Migraine; Myocardial infarction; Stroke

Mesh:

Substances:

Year:  2019        PMID: 30879200     DOI: 10.1007/164_2019_204

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  5 in total

Review 1.  Drug Safety in Episodic Migraine Management in Adults. Part 2: Preventive Treatments.

Authors:  Abigail L Chua; Sandhya Mehla; Yulia Y Orlova
Journal:  Curr Pain Headache Rep       Date:  2022-05-19

2.  Calcitonin gene-related peptide-targeting drugs and Raynaud's phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database.

Authors:  Michel Lantéri-Minet; Milou-Daniel Drici; Alexandre O Gérard; Diane Merino; Elise K Van Obberghen; Fanny Rocher; Alexandre Destere
Journal:  J Headache Pain       Date:  2022-05-03       Impact factor: 8.588

Review 3.  The Vascular-Dependent and -Independent Actions of Calcitonin Gene-Related Peptide in Cardiovascular Disease.

Authors:  Fulye Argunhan; Susan D Brain
Journal:  Front Physiol       Date:  2022-02-25       Impact factor: 4.566

4.  Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2'-O-Methylation of Viral RNA.

Authors:  José Antonio Encinar; Javier A Menendez
Journal:  Viruses       Date:  2020-05-10       Impact factor: 5.048

5.  Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients.

Authors:  Fumihiko Sakai; Norihiro Suzuki; Byung-Kun Kim; Hisaka Igarashi; Koichi Hirata; Takao Takeshima; Xiaoping Ning; Tomoko Shima; Miki Ishida; Katsuhiro Iba; Hiroyuki Kondo; Nobuyuki Koga
Journal:  Headache       Date:  2021-07-29       Impact factor: 5.887

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.